Overview
This is a multicenter, prospective, registry study. By collecting relevant demographic information and clinical data of patients receiving continuous renal replacement therapy (CRRT) with pre-mixed solutions, the clinical applicability of pre-mixed solutions will be evaluated in critically ill patients in real-world clinical settings.
This study will be carried out in approximately 10 study sites in China. Patient data will be collected to evaluate the clinical applicability of pre-mixed solutions.
Description
Treatment observation period: From initiation of the first CRRT with sponsored pre-mixed solutions to cessation of the pre-mixed solutions. The duration of this period can be up to 10 days.
Follow-up period: from the cessation of sponsored pre-mixed solutions to Day 30 after starting treatment with the pre-mix solutions.
Eligibility
Inclusion Criteria:
- 18 ≤ age < 80 years old.
- Patients admitted to the intensive care unit (ICU) and in need of CRRT.
- Patients are willing to receive CRRT with at least one of three pre-mixed solutions:
Regiocit, Biphozyl, or Prismasol 2.
Exclusion Criteria:
- Patients with chronic kidney failure who are receiving maintenance dialysis.
- Patients expected to require the premixed solution for less than 24 hours.
- Patients who are allergic or have contraindications to components of pre-mixed solutions, as determined by the investigators.
- Patients who have participated in other interventional studies within the last 30 days.
- Patients who are pregnant, breastfeeding, or abortus imminence.